• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OCUL

    Ocular Therapeutix Inc.

    Subscribe to $OCUL
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of Dry Age-related Macular Degeneration. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: ocutx.com

    Peers

    $EYEG

    Recent Analyst Ratings for Ocular Therapeutix Inc.

    DatePrice TargetRatingAnalyst
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    4/21/2023$18.00Outperform
    Robert W. Baird
    8/10/2022$15.00Buy
    Berenberg
    3/1/2022$30.00 → $22.00Market Outperform
    JMP Securities
    See more ratings

    Ocular Therapeutix Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

      AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular is actively planning next steps in NPDR and DME SOL-1 retention remains exceptional as trial is on track for 1Q 2026 topline data readout SOL-R continues to have strong enrollment through streamlined, accelerated execution Cash balance of $349.7M as of March 31, 2025, with expected runway through topline data for SOL-1 and SOL-R and into 2028 BEDFORD, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharma

      5/5/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

      BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in the first half of May 2025. Upcoming Investor Conferences Citizens JMP Life Sciences Conference 2025:Fireside Chat Date: Wednesday, May 7, 2025Fireside Chat Time: 9:00 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY Bank of America 2025 Global Healthcare Conference:Fireside Chat Date: Tuesday, May 13, 2025Fireside Chat Time: 9:20 AM PTPresenter: Pravin U. Dugel, MD, Executive C

      4/29/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

      BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

      4/28/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Executive Director, Payer Access, Thomas J. Cella, and one other newly hired non-executive employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of April 7, 2025 and consist of (i) for Mr. Cella, a non-statutory stock option to

      4/11/25 4:30:00 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Participate in Two Investor Conferences in April

      BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April: 24th Annual Needham Virtual Healthcare ConferencePresentation Date: Monday, April 7, 2025Presentation Time: 3:00 PM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Virtual Piper Sandler Spring Biopharma SymposiumDate: Thursday, April 17, 2025Ocular Therapeutix to host investor one-on-one meetingsLocation: Boston, MA A live webcast of the Needham presentation can be accessed by visiting the Ocul

      3/31/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of March 3, 2025 and consist of (i) a non-statutory stock option to purchase up to 48,000 shares of Ocular's common stock at a per share exercise price equal to the closing pric

      3/7/25 4:05:00 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

      Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional retention seen to date in the study, paves way for reduction of SOL-R trial size to 555 subjects (previously 825), potentially accelerating registration timelines Additional updates provided on SO

      3/3/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Present at Two Investor Conferences in March

      BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in March: TD Cowen 45th Annual Health Care Conference Presentation DetailsFireside Chat Date: Tuesday, March 4, 2025Fireside Chat Time: 11:50 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Boston, MA Leerink Partners Global Healthcare Conference 2025Fireside Chat Date: Monday, March 10, 2025Fireside Chat Time: 10:00 AM ET Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Mi

      2/25/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

      BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201) 689-8470 Conference ID: 13750940 Webcast Access: Please click here The live and archived webcast can also be acce

      2/24/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

      BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. Presentation Details: OTX-TKI From Phase 1 to Phase 3: SOL-1 and SOL-R Trials for Neovascular AMDSession: V: Imaging and Emerging Therapies for Exudative AMDPresentation Time: 2:30 PM ETPresenter: Carl J. Danzig, MD Phase 1 Results from Intravitreal Axitinib Implant (OTX-TKI) for the Treatment of Non-Proliferative Diabetic RetinopathySession: VII: Diabetic Retinopathy and Re

      2/3/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ocular Therapeutix Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Ocular Therapeutix

      William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

      4/8/25 9:29:59 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

      RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

      3/18/25 7:53:57 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Ocular Therapeutix with a new price target

      Needham initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $15.00

      3/11/25 7:42:03 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Ocular Therapeutix

      Scotiabank initiated coverage of Ocular Therapeutix with a rating of Sector Outperform

      10/16/24 8:39:33 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix upgraded by TD Cowen with a new price target

      TD Cowen upgraded Ocular Therapeutix from Hold to Buy and set a new price target of $11.00 from $7.00 previously

      6/20/24 7:36:07 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Ocular Therapeutix with a new price target

      Piper Sandler resumed coverage of Ocular Therapeutix with a rating of Overweight and set a new price target of $15.00

      5/31/24 7:46:11 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Ocular Therapeutix with a new price target

      BofA Securities initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $15.00

      2/9/24 6:24:06 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Ocular Therapeutix with a new price target

      Robert W. Baird initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $18.00

      4/21/23 7:41:49 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg resumed coverage on Ocular Therapeutix with a new price target

      Berenberg resumed coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $15.00

      8/10/22 7:20:40 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Ocular Therapeutix with a new price target

      JMP Securities reiterated coverage of Ocular Therapeutix with a rating of Market Outperform and set a new price target of $22.00 from $30.00 previously

      3/1/22 7:05:45 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ocular Therapeutix Inc. Financials

    Live finance-specific insights

    See more
    • Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

      BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

      4/28/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

      Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional retention seen to date in the study, paves way for reduction of SOL-R trial size to 555 subjects (previously 825), potentially accelerating registration timelines Additional updates provided on SO

      3/3/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

      BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201) 689-8470 Conference ID: 13750940 Webcast Access: Please click here The live and archived webcast can also be acce

      2/24/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

      SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 conference call and webcast today, November 14th, at 8:00 AM ET BEDFORD, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the

      11/14/24 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

      BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024. Conference Call and Webcast Information: Date: Thursday, November 14, 2024, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201)

      11/6/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Second Quarter 2024 Results

      SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M as of June 30, 2024, Expected to Fund Operations into 2028 Ocular Will Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the se

      8/7/24 7:10:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

      Clear Regulatory Path for AXPAXLI™ in Wet AMD Through Ongoing SOL-1 and SOL-R Registration-Enabling Trials Ocular to Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company has received a written response from the U.S. Food and Drug Administration (FDA) that the Phase 3 SOL-R clinical trial is appropriate for use as the

      8/7/24 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

      BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024. Conference Call and Webcast Information:Date: Wednesday, August 7, 2024, at 8:00 AM ETParticipant Dial-In (U.S.): 1 (800) 343-4136Participant Dial-in (International): 1 (203) 518-9843Confer

      7/31/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

      First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second quarter 2024 financial results BEDFORD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced plans to report first quarter 2024 financial results on Tue

      5/1/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

      BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for retinal disease and other diseases and conditions of the eye, today announced plans to report the Company's fourth quarter and full year 2023 financial results on Monday, March 11, 2024, after 4:00 p.m. Eastern Time. Given the recent corporate announcements regarding leadership appointments and the closing of a $325 million private placement, the Company will not host a conference call to discuss its fourth quarter and full

      3/5/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ocular Therapeutix Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 5:49:38 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ocular Therapeutix Inc.

      SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 9:37:26 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/12/24 4:49:23 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/4/24 1:42:09 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Ocular Therapeutix Inc. (Amendment)

      SC 13D/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      2/27/24 4:30:18 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ocular Therapeutix Inc. (Amendment)

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      2/14/24 7:48:57 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ocular Therapeutix Inc. (Amendment)

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      2/13/24 5:09:46 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ocular Therapeutix Inc. (Amendment)

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      1/31/24 2:08:26 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ocular Therapeutix Inc.

      SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      12/28/23 4:17:19 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ocular Therapeutix Inc.

      SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      12/22/23 4:04:01 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ocular Therapeutix Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Ocular Therapeutix Inc.

      10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:47:55 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:06:05 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ocular Therapeutix Inc.

      DEFA14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      4/29/25 5:01:27 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Ocular Therapeutix Inc.

      DEF 14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      4/29/25 5:00:21 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Ocular Therapeutix Inc.

      PRE 14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      4/18/25 4:28:40 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Ocular Therapeutix Inc.

      10-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      3/3/25 7:19:42 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      3/3/25 7:07:02 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Ocular Therapeutix Inc.

      144 - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      2/24/25 4:33:36 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix Inc. filed SEC Form 8-K: Leadership Update

      8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      2/14/25 7:32:26 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Ocular Therapeutix Inc.

      S-8 - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      11/14/24 7:30:26 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ocular Therapeutix Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/27/24 4:43:51 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summer Road Llc bought $4,999,998 worth of shares (1,538,461 units at $3.25) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      12/18/23 4:52:33 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ocular Therapeutix Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Dugel Pravin sold $147,533 worth of shares (21,475 units at $6.87), decreasing direct ownership by 0.61% to 3,520,318 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:27:13 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Heier Jeffrey S. sold $21,029 worth of shares (3,061 units at $6.87), decreasing direct ownership by 1% to 265,998 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:25:32 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Kaiser Peter sold $20,672 worth of shares (3,009 units at $6.87), decreasing direct ownership by 1% to 210,078 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:24:08 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Strategy Officer Nayak Sanjay sold $12,962 worth of shares (1,895 units at $6.84), decreasing direct ownership by 0.66% to 283,485 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:22:06 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dugel Pravin was granted 2,750,000 shares, increasing direct ownership by 347% to 3,541,793 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/13/25 8:38:44 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Waheed Nadia was granted 79,000 shares, increasing direct ownership by 56% to 220,666 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/13/25 8:37:32 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Notman Donald was granted 115,000 shares, increasing direct ownership by 59% to 308,444 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/13/25 8:36:23 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Strategy Officer Nayak Sanjay was granted 111,000 shares, increasing direct ownership by 64% to 285,380 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/13/25 8:35:06 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Notman Donald sold $136,239 worth of shares (17,420 units at $7.82), decreasing direct ownership by 8% to 193,444 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/4/25 7:16:20 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Heier Jeffrey S. sold $26,561 worth of shares (2,948 units at $9.01), decreasing direct ownership by 1% to 269,059 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      11/27/24 7:52:55 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ocular Therapeutix Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Ocular Therapeutix® to Host Investor Day on June 13, 2024

      Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

      6/5/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports First Quarter 2024 Results

      Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

      5/7/24 4:05:00 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

      Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc

      4/16/24 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

      Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay Nayak, MBBS, PhD to become Chief Strategy Officer Addition of Strategic and Clinical Experts Puts Ocular on Track to be a Leader in Retina Care Expanded Team Anticipated to Accelerate Momentum in AXPAXLI™ Phase 3 Wet AMD Programs BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapi

      2/22/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

      BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Steve Meyers as Chief Commercial Officer. "As we continue our commitment to advancing our drug portfolio in order to enhance the quality of life for patients, I am thrilled to announce the promotion of Steve Meyers to the role of Chief Commercial Officer," said Antony Mattessich, CEO of Ocular Therapeutix. "Steve has consistently demonstrated exceptional leadership, strategic vision and a deep understanding of

      2/15/24 8:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Announces Appointment of New Board Member

      BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors. A visual scientist by training and a global industry leader in ophthalmology, Dr. Graves brings extensive experience to her role. As the former CEO of Santen Inc., the US subsidiary of a 130-year-old Japanese pharmaceutical company, she successfully established a strong global presence, bringing multiple ophthalmic products through development to approval and c

      7/12/23 8:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer

      Leading Ophthalmologist and Experienced Industry Executive to Advance Development of Innovative Corneal Endothelial Cell Therapy Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer. Dr. Goldstein will lead the Company's clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cell therapy to treat corneal edema secondary to endothelial dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.c

      6/9/22 8:00:00 AM ET
      $AGTC
      $OCUL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations

      Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations. Dr. Edwards will join the senior leadership team and be responsible for technical development, manufacturing, quality and supply chain operations. "We are excited to welcome Karen-Leigh to the Ocular team," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "With experience across multiple disciplines at several leading pharmaceutical companies, Karen-Leigh's pr

      9/28/21 8:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

      Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021. "We are excited to welcome Merilee to our Board of Directors," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from sta

      9/22/21 8:00:00 AM ET
      $IDXX
      $OCUL
      $TMDX
      $WTS
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development

      BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the promotion of Michael Goldstein, MD, MBA, to the newly created position of President, Ophthalmology. Dr. Goldstein will continue to report to Antony Mattessich, Ocular’s President and Chief Executive Officer. With this promotion, Dr. Goldstein will be responsible for clinical operations and in that capacity will maintain his role as Chief Medical Officer. He will also be responsible for commercial operations in alignment with the overall Co

      1/7/21 8:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care